Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BM-MSC Transplantation for Kienböck's Disease
NCT02646007Phase 1Unknown
- Sponsor
- Royan Institute
- Start
- Nov 2015
- Primary completion
- Nov 2018
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Provacel in Kienböck's disease, sponsored by Royan Institute. Primary endpoints: Pain at 3 months and Bone density at 3 months. Status: unknown.
02
Drugs
Provacel
03
Conditions
Kienböck's disease
Beyond the preview
Go deeper on NCT02646007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02646007.